BACKGROUNDGemcitabine-based (GEM-based) chemotherapy remains a mainstay of treatment for cholangiocarcinoma (CCA); however, acquired resistance substantially limits its clinical efficacy.Members of the solute carrier family 25 (SLC25) have been implicated in tumorigenesis and therapeutic resistance, SLC25A18/TGFBR1 assessment may provide exploratory prognostic information, while its value for predicting GEM response and therapeutic targeting remains to be established.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: